Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Incyte's experimental skin disease drug met the main goal of two separate late-stage trials, but data showed that it was not as effective as in its prior studies, sending the drugmaker's shares down ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Incyte's experimental skin disease drug met the main goal of two separate late-stage trials, the company said on Monday, but its shares declined 11% as the drug significantly underperformed prior ...

Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

Investing.com -- Shares of Incyte Corporation (NASDAQ: INCY) fell 14% after the biopharmaceutical company announced topline results from two Phase 3 clinical trials of povorcitinib in patients with ...

Opponents, including Premier Doug Ford, argue supervised consumption sites enable addiction, but users and staff say they ...